The effect of catechol-O-methyltransferase polymorphism on the levodopa pharmacokinetics after co-administration of single dose of levodopa and entacapone in Parkinsonian patients

被引：0
|
作者：
Wu, RM
Yu, IW
Ho, YF
Kuo, JW
Chern, H
机构：
来源：
MOVEMENT DISORDERS | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P119
引用
收藏
页码：S50 / S51
页数：2
相关论文
共 50 条
  • [31] The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease
    Torkaman-Boutorabi, Anahita
    Shahidi, Gholam Ali
    Choopani, Samira
    Rezvani, Mohammad
    Pourkosary, Kosar
    Golkar, Majid
    Zarrindast, Mohammad-Reza
    ACTA NEUROBIOLOGIAE EXPERIMENTALIS, 2012, 72 (03) : 272 - 282
  • [32] Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson’s disease
    Cuiping Zhao
    Yihua Wang
    Bin Zhang
    Yaoxian Yue
    Jianyuan Zhang
    Scientific Reports, 10
  • [33] Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease
    Mueller, T.
    Erdmann, C.
    Muhlack, S.
    Bremen, D.
    Przuntek, H.
    Goetze, O.
    Woitalla, D.
    JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (10) : 1441 - 1448
  • [34] Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease
    T. Müller
    C. Erdmann
    S. Muhlack
    D. Bremen
    H. Przuntek
    O. Goetze
    D. Woitalla
    Journal of Neural Transmission, 2006, 113 : 1441 - 1448
  • [35] CYP2D6 and catechol-O-methyltransferase gene polymorphisms in Parkinson patients with levodopa-induced dyskinesias
    Ivanova, S. A.
    Alifirova, V. M.
    Pozhidaev, I. V.
    Fedorenko, O. Y.
    Osmanova, D. Z.
    Tiguntsev, V. V.
    Bokhan, N. A.
    Zhukova, I. A.
    Wilffert, B.
    Loonen, A. J. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S656 - S657
  • [36] Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson’s disease
    Thomas Müller
    Dirk Woitalla
    Siegfried Muhlack
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 383 : 627 - 633
  • [37] Levodopa-related cysteinyl–glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients
    Thomas Müller
    Siegfried Muhlack
    Journal of Neural Transmission, 2014, 121 : 643 - 648
  • [38] Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease
    Mueller, Thomas
    Woitalla, Dirk
    Muhlack, Siegfried
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2011, 383 (06) : 627 - 633
  • [39] Effect of nebicapone (BIA 3-202) on the the pharmacokinetics of levodopa and catechol O-methyltransferase (COMT) activity in patients with Parkinson's disease
    Almeida, Luis
    Ferreira, Joaquim
    Nunes, Teresa
    Machado, Rita
    Torrao, Leonel
    Costa, Joana
    Soares, Eva
    Rocha, Jose
    Falcao, Amilcar
    Wright, Lyndon
    Soares-da-Silva, Patricio
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (06) : 784 - 785
  • [40] Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients
    Mueller, Thomas
    Muhlack, Siegfried
    JOURNAL OF NEURAL TRANSMISSION, 2014, 121 (06) : 643 - 648
12345